Skin disorders, Medicines planning
4 results
Applied filters
Preparing to use ustekinumab biosimilar
31 July 2026Introducing biosimilar ustekinumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
The licence and supporting evidence for ustekinumab biosimilars
31 July 2026Ustekinumab biosimilars are available for use within the NHS. Learn about indications, formulations, supporting evidence and differences.
The licence and supporting evidence for omalizumab biosimilar
20 July 2026Adcomfo, a second omalizumab biosimilar alongside Omlyclo, is now licensed. Review its indications, evidence, and main differences.
Preparing to use omalizumab biosimilar
20 July 2026Adcomfo, a second omalizumab biosimilar alongside Omlyclo, is now licensed. We offer general information and implementation advice.